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A B S T R A C T
Purpose
In the ESTIMABL phase III trial, the thyroid ablation rate was equivalent for the two thyroid-
stimulating hormone (TSH) stimulation methods (thyroid hormone withdrawal [THW] and recom-
binant human TSH [rhTSH]) and the two iodine-131 (131I) activities (1.1 or 3.7 GBq). The objectives
of this article were to present health-related quality-of-life (HRQoL) results and a cost-
effectiveness evaluation performed alongside this trial.
Patients and Methods
HRQoL and utility were longitudinally assessed, from random assignment to the follow-up visit at
8  2 months for the 752 patients with thyroid cancer, using the Short Form-36 and the
EuroQoL-5D questionnaires, respectively. A cost-effectiveness analysis was performed from the
societal perspective in the French context. Resource use (hospitalization for 131I administration,
rhTSH, sick leaves, and transportation) was collected prospectively. We used the net monetary
benefit approach and computed cost-effectiveness acceptability curves for both TSH stimulation
methods and 131I activities. Sensitivity analyses of the costs of rhTSH were performed.
Results
At 131I administration, THW caused a clinically significant deterioration of HRQoL, whereas HRQoL
remained stable with rhTSH. This deterioration was transient with no difference 3 months later.
rhTSH was more effective than THW in terms of quality-adjusted life-years (QALYs; 0.013
QALY/patient) but more expensive (€474/patient). The probability that rhTSH would be cost
effective at a €50,000/QALY threshold was 47% in France. The use of 1.1 GBq of 131I instead of
3.7 GBq reduced per-patient costs by €955 (US$1,018) but with slightly decreased efficacy
(0.007 QALY/patient).
Conclusion
rhTSH avoids the transient THW-induced deterioration of HRQoL but is unlikely to be cost
effective at its current price.
J Clin Oncol 33:2885-2892. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Radioiodine (iodine-131 [131I]) is administered to
patients with thyroid cancer after total thyroidec-
tomy to eradicate persistent normal or neoplastic
thyroid tissue.1-3 This is ablation that is defined at
8  2 months after radioiodine administration by
the absence of abnormalities on neck ultrasonogra-
phy and undetectable serum thyroglobulin levels.
Stimulation by thyroid-stimulating hormone (TSH) is
needed to promote iodine uptake by thyroid cells,
and this is achieved either through thyroid hormone
withdrawal (THW) for 3 to 5 weeks or recombinant
human TSH (rhTSH) injections. In 2006, Pacini et
al4 demonstrated similar efficacy between rhTSH
and THW for ablation with 3.7 GBq of 131I in a
noninferiority trial comprising 66 patients. Recently,
the Etude Stimulation Ablation (ESTIMABL) phase
III randomized trial comprising 752 French pa-
tients with thyroid cancer confirmed that the thy-
roid ablation rate was equivalent for the two
methods of TSH stimulation (THW or rhTSH)
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and also for the two 131I activities (1.1 or 3.7 GBq).5 Similar results
were found in the HiLo (Multicentre Randomised Trial of High
Dose Versus Low Dose Radioiodine, With or Without Recombi-
nant Human Thyroid Stimulating Hormone, for Remnant Abla-
tion Following Surgery for Differentiated Thyroid Cancer) phase
III trial of 450 British patients.6
Hypothyroidism induced by THW is known to deteriorate the
health-related quality of life (HRQoL).7-9 In the trial by Pacini et al,4
rhTSH avoided HRQoL deterioration induced by THW. However,
the HRQoL evaluation was restricted to the periablation period. To
date, the impact of iodine activity on HRQoL has not been evaluated.
rhTSH was shown to reduce the hospital stay10 and the duration
of sick leaves11 in nonrandomized studies, making it possible to par-
tially compensate its acquisition cost. However, the three cost-utility
analyses based on Markov models that compared the use of either
rhTSH or THW for ablation with 3.7 GBq of 131I yielded discordant
results.12-14 Mernagh et al12 found that rhTSH was cost effective (the
incremental cost-effectiveness ratio [ICER] of €958 per quality-
adjusted life-year [QALY] was lower than the most commonly used
$50,000/QALY willingness-to-pay threshold) in the German context,
and these results were confirmed in the Canadian setting (ICER,
$1,520/QALY) using the same model.13 In the US context, the use of
rhTSH yielded an ICER of $52,554/QALY.14 These studies were lim-
ited by the fact that data were either extracted from the literature
(retrospective studies) or based on expert opinions. Sensitivity analy-
ses showed that the greatest uncertainties concerned the duration of
sick leaves and the length of hospital stays.15 Moreover, because life
expectancy of patients with thyroid cancer is generally not shortened
by the disease, QALY assessments are particularly relevant. The cur-
rent literature is lacking rigorous data, and utility values have been
rarely assessed using a standard preference-based questionnaire.16
Thyroid cancer has a significant economic and societal impact, with
annualestimatedcostsofcareexceeding$1.6billionintheUnitedStatesin
2013.17 Substantial costs are related to the diagnosis and treatment of
newly diagnosed patients and to the ongoing follow-up in these patients
with good prognosis. The clinical equivalence of the new radioiodine
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Fig 1. CONSORT diagram. rhTSH, recombinant human thyroid-stimulating hormone; TWH, thyroid hormone withdrawal.
Table 1. Unit Cost and Sources
Resource Unit Cost (€) Source
Drug
rhTSH (Thyrogen; Genzyme, Cambridge, MA) €379 per vial Drug consumption database published in France21
Hospital stay
Variable cost (per stay) €508 French National Cost Survey, using the 10M121
diagnosis-related group code
Fixed cost for 1 day in the hospital (inpatient) for radioiodine administration €510
Transportation cost
Ambulance €57  €2/km French health insurance reimbursement tariffs
Patient transport car €13  €1/km
Taxi €2  €1/km
Personal car €0.32/km
Indirect costs
Average daily wage (loss of productivity) €198 per day National added value per inhabitant
NOTE. €1  US$1.066.
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ablation strategies needs to be balanced against their impact on HRQoL
and costs. By avoiding prolonged THW, rhTSH is expected to maintain
HRQoL and decrease the duration of sick leave and hospital stay. Because
rhTSH is an expensive drug, its routine use should be supported by an
economic evaluation. Low radioiodine activity is expected to reduce the
length of hospital stay, but its impact on HRQoL and cost-effectiveness is
unknown. In this study, we present HRQoL findings and a cost-
effectiveness evaluation performed alongside the ESTIMABL trial.
PATIENTS AND METHODS
ESTIMABL Trial Design
We used patient-level data from the ESTIMABL trial (trial-based ap-
proach). This was a multicenter phase III trial where patients with thyroid
cancer who underwent total thyroidectomy were randomly assigned to one of
four strategies, with each strategy combining one TSH stimulation method
(THW or rhTSH) and one 131I activity (1.1 or 3.7 GBq; Fig 1).5 The trial was an
equivalence study using a two-by-two factorial design to answer whether the
successful ablation rate at 8  2 months obtained with rhTSH was within 10%
of that obtained with THW and the successful ablation rate with 1.1 GBq of 131I
was within 10% of that obtained with 3.7 GBq. In the 684 evaluable patients, it
was equivalent for both I31I activities and TSH stimulation methods.5 Second-
ary outcomes included HRQoL, hypothyroid symptoms and toxicities, direct
and indirect costs, and cost-effectiveness.
HRQoL and Utility
Quality of life (QoL) was assessed using the self-administered Short
Form-36 (SF-36; with an acute recall period) at random assignment (when all
patients were euthyroid on l-thyroxine therapy), immediately before 131I ad-
ministration, at 6 weeks after radioiodine administration, and at 3 and 8
months. The SF-36 questionnaire was used to describe the QoL because it has
been shown to be sensitive in patients with thyroid cancer.4,7 At each visit,
scores were allotted for the eight dimensions and for the physical component
summary (PCS) and mental component summary (MCS). Clinically signifi-
cant deterioration was defined as a decrease of 5 points or more in the PCS or
MCS scores compared with the baseline scores.18 The proportion of patients
with clinically significant deterioration was compared between treatments at
each time point, using a 2 test, with a corrected P value for multiple testing.
Logistic mixed models were used to assess the longitudinal impact of treat-
ments on repeated measures of HRQoL, with the probability of having clini-
cally significant deterioration on either PCS or MCS (successively) as a
dependent variable. The models tested the treatment effect (either the TSH
stimulation method or the 131I activity successively), the time points (four
visits after random assignment), and the interaction between treatment and
time as fixed effects.
The EuroQoL (EQ) -5D questionnaire, a preference-based measure, was
used to assess utility and QALYs. Questionnaires were collected seven times (at







































































































































Fig 2. Mean difference in the Short
Form (SF) -36 scores between random
assignment and iodine administration,
according to the thyroid-stimulating hor-
mone (TSH) stimulation method. A signif-
icant difference in all SF-36 scores was
observed between the two TSH stimula-
tion methods at iodine-131 (131I) adminis-
tration (P  .001), particularly in the
“Limitations due to physical functioning”
and “Fatigue” dimensions. Thyroid hor-
mone withdrawal (THW) caused a signifi-
cant deterioration of health-related quality
of life (HRQoL), whereas HRQoL was
maintained in recombinant human TSH
(rhTSH) patients. A higher proportion of
patients in the THW groups reported clin-
ically significant HRQoL deterioration at
131I administration compared with the
rhTSH groups (50% v 25%, respectively,
for physical component summary; 50% v
32%, respectively, for mental component
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Fig 3. Evolution of the physical component summary (PCS) and mental
component summary (MCS) scores during the follow-up period according to the
thyroid-stimulating hormone (TSH) stimulation method. Ninety-seven percent of
the expected Short Form-36 questionnaires were returned, whatever the visit or
treatment group. Patients prepared by thyroid hormone withdrawal (THW)
experienced deterioration on both PCS and MCS scores at the time of radioiodine
(131I) administration. Thereafter, health-related quality of life (HRQoL) improved,
and there was no difference in HRQoL between the two TSH stimulation
methods 3 months later. rhTSH, recombinant human TSH.
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after radioiodine administration; and at the 3- and 8-month visits) to measure
the evolution of utility scores over that period. At each assessment, the utility
value was obtained through the utility function, which was calculated based on
the revealed preferences of the French population.19 For each patient, QALYs
were assessed by weighting the time period between two consecutive visits
with the utility value, assuming a linear change in utility over time (ie, using
a trapezoidal area formula). QALYs were obtained by summing values for
each time interval and were adjusted for unbalanced baseline values be-
tween groups.20
Resource Use and Costs
Resource use was prospectively collected alongside the ESTIMABL trial
until the thyroid ablation assessment at 8 months. It included hospitalization
for 131I administration, rhTSH, sick leaves, and transportation. Costs were
assessed from the French societal perspective and were expressed in 2013 euros
(results are also presented in US dollars using the conversion rate of €1 
US$1.066). Unit costs data are listed in Table 1. rhTSH was used for radioio-
dine administration exclusively in the rhTSH groups (two vials) and in all
patients during the visit at 8 months (two vials). To account for the economic
impact of the reduction in the length of hospital stay, the cost per stay was
calculated distinguishing between fixed costs per day (staff, equipment, and
overhead) and variable costs per stay (resources required for 131I administra-
tion, rhTSH, and radioiodine activity). Fixed and variable costs were extracted
from the French National Cost Survey, using the diagnosis-related group code
for 131I administration. The price of rhTSH was obtained from the French
drug database.21 Indirect costs were evaluated based on the loss of productivity
incurred by sick leave using the friction cost approach. One day off work
translated into 0.8 day of lost productivity to adapt the adjustment time period
to absenteeism.22,23 The value of lost productivity was based on the national
added value estimated at €198 (US$211) per day. Transportation costs were
estimated using the French health insurance reimbursement tariffs, according
to the home-hospital distance and the type of transportation used. Mean cost
per patient was calculated with and without indirect costs, according to the
French guidelines for cost-effectiveness studies.24 Mean costs were compared
between groups using nonparametric Wilcoxon tests.
Cost-Effectiveness Analysis
The time horizon was fixed at 8  2 months because no difference in
utility scores or costs between strategies was expected after thyroid ablation
assessment. Whatever the strategy, all patients had the same life expectancy (no
death occurred during the 8-month period).
We used the net monetary benefit approach to compare the stimulation
methods and the radioiodine activities.25 A nonparametric bootstrap with
10,000 replications (percentile method) was used to estimate the 95% CIs for
costs, QALYs, and cost-effectiveness acceptability curves. A one-way sensitiv-
ity analysis was performed reducing the price of rhTSH by 10% and 30%,
because a biosimilar of rhTSH may be available in the future.
Table 2. Descriptive Results Obtained With the EuroQol-5D at Radioiodine Ablation by Method of Stimulation and Radioiodine Activity
Dimension and Level
No. of Patients (%)
TSH Stimulation Method Radioiodine Activity
THW (n  336) rhTSH (n  348) 3.7 GBq (n  337) 1.1 GBq (n  347)
Mobility
No problems (1) 292 (86.9) 325 (93.4) 307 (91.1) 310 (89.3)
Some problems (2) 39 (11.6) 21 (6.0) 29 (8.6) 31 (8.9)
Confined to bed (3) 1 (0.3) 1 (0.3) 1 (0.3) 1 (0.3)
Missing 4 (1.2) 1 (0.3) 0 (0) 5 (1.4)
Self-care
No problems (1) 327 (97.3) 342 (98.3) 332 (98.5) 337 (97.1)
Some problems (2) 5 (1.5) 5 (1.4) 5 (1.5) 5 (1.4)
Unable to (3) 0 (0) 0 (0) 0 (0) 0 (0)
Missing 4 (1.2) 1 (0.3) 0 (0) 5 (1.4)
Usual activities
No problems (1) 264 (78.6) 299 (85.9) 278 (82.5) 285 (82.1)
Some problems (2) 65 (19.3) 45 (12.9) 56 (16.6) 54 (15.6)
Extreme (3) 3 (0.9) 2 (0.6) 3 (0.9) 2 (0.6)
Missing 4 (1.2) 2 (0.6) 0 (0) 6 (1.7)
Pain discomfort
None (1) 186 (55.4) 203 (58.3) 188 (55.8) 201 (57.9)
Moderate (2) 138 (41.1) 137 (39.4) 140 (41.5) 135 (38.9)
Extreme (3) 8 (2.4) 6 (1.7) 9 (2.7) 5 (1.4)
Missing 4 (1.2) 2 (0.6) 0 (0) 6 (1.7)
Anxiety/depression
None (1) 162 (48.2) 157 (45.1) 156 (46.3) 163 (47.0)
Moderate (2) 161 (47.9) 172 (49.4) 168 (49.9) 165 (47.6)
Extreme (3) 9 (2.7) 18 (5.2) 13 (3.9) 14 (4.0)
Missing 4 (1.2) 1 (0.3) 0 (0) 5 (1.4)
Patients in perfect health state (all levels  1) 100 (29.8) 100 (28.7) 98 (29.0) 102 (29.4)
Utility score
Mean 0.833 0.849 0.836 0.846
Standard deviation 0.192 0.173 0.184 0.182
Range 0.302 to 1.000 0.018 to 1.000 0.018 to 1.000 0.302 to 1.000
NOTE. At radioiodine administration, patients stimulated by THW had significantly more problems with mobility (P  .03) and usual activities (P  .05) than patients
stimulated by rhTSH without differences on other dimensions, as shown by the EuroQol-5D questionnaire.
Abbreviations: rhTSH, recombinant human thyroid-stimulating hormone; THW, thyroid hormone withdrawal.
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Statistical Analysis
Analyses of HRQoL and cost-effectiveness were performed according to
the 2  2 factorial design on the 684 evaluable patients for the main outcome.5
The number of patients required in the ESTIMABL trial was not calculated to
detect a difference in the MCS or PCS score. However, this number allowed the
detection of a minimal difference of 13%. The analyses were performed using
the SAS software version 9.1 (SAS Institute, Cary, NC).
RESULTS
HRQoL
Ninety-seven percent of the expected SF-36 questionnaires were
returned. Patients who had undergone THW exhibited a significant
deterioration (P  .001) of HRQoL at 131I administration compared
with rhTSH patients (Fig 2). The greatest deterioration was observed
in physical health-related and vitality domains, but all domains were
significantly affected. A higher proportion of patients reported clini-
cally significant HRQoL deterioration at 131I administration in the
THW groups compared with the rhTSH groups (50% v 25%, respec-
tively, for PCS; 50% v 32%, respectively, for MCS; both P  .001).
Thereafter, HRQoL improved, and no significant difference in
HRQoL scores was observed at subsequent follow-up visits (Fig 3). 131I
activity did not have any impact on HRQoL.
Using the EQ-5D questionnaire, at 131I administration, THW
patients had significantly more problems with mobility and usual
activities than rhTSH patients, translating into a lower utility score
(estimated at 0.833 and 0.849, respectively; Table 2). Utility scores of
THW patients continued to decrease for 2 weeks after radioiodine
administration and then increased; a similar evolution was observed
with utility scores obtained from SF-36 questionnaires (Appendix Fig
A1, online only). Over 8 months, mean QALY reached 0.675 and
0.687 per patient stimulated by THW or rhTSH, respectively. Because
there was no difference in survival, the QALY difference was only
explained by the utility values.
Resource Use and Costs
The length of hospital stay for 131I administration was similar in
the rhTSH and THW groups (2.6 v 2.8 days, respectively), as was sick
leave time (23 v 24 days, respectively). Concerning the radioiodine
activity, the length of hospital stay was significantly shorter in
patients receiving 1.1 GBq compared with 3.7 GBq (2.3 v 3.2 days,
respectively; P  .001), but no difference was observed in the
length of sick leaves (22 v 25 days, respectively). There was no
difference in the type of transportation.
Mean direct costs were estimated at €3,413 (US$3,638) per
rhTSH patient and €2,734 (US$2,914) per THW patient. The use of
rhTSH was associated with an extra cost of €679 per patient, mainly as
a result of its price. Mean direct cost was lower in patients treated with
1.1 GBq than with 3.7 GBq (€2,847 and €3,318, respectively) as a result
of a shorter hospital stay (Table 3).
Cost-Effectiveness Analysis
Over the 8-month period, the use of rhTSH was more effective in
terms of QALYs (mean increase of 0.013 QALY per patient) but was
more expensive than THW (Table 3). With the threshold of €50,000/
QALY (US$53,300/QALY), the probability that rhTSH would be
cost effective was 47% and 59% when direct and total (direct plus
indirect) costs were considered, respectively (Fig 4 and Appendix
Fig A2, online only). When the rhTSH price was lowered by 30%,
the extra cost incurred with rhTSH was reduced (€452 for direct
costs) and the probability that rhTSH would be cost effective for a
threshold of €50,000/QALY increased to 70% (Appendix Fig A4,
online only).
The use of 1.1 GBq instead of 3.7 GBq of 131I led to a small decline
in QALYs (mean decrease of 0.007 QALY) but was also cheaper
(Table 3). At the threshold of €50,000/QALY, the probability that the
lower 131I activity would be cost effective was 65% and 77% when
direct and total costs were considered, respectively (Appendix Figs A2
and A3).
DISCUSSION
At 131I administration, HRQoL was significantly better in all the SF-36
domains for rhTSH patients than after THW,7,8 because rhTSH
avoids hypothyroidism. This effect was transient, and there was no
difference in HRQoL 3 months after 131I administration. Given the
current price of rhTSH, it is unlikely to be cost effective at a threshold
of €50,000/QALY. The availability of an rhTSH biosimilar in the
future will probably allow a price reduction and better value for
money. Regarding radioiodine activity, there was no impact on
HRQoL, but cost-effectiveness results favor the use of a low 131I activ-
ity because it shortened the length of hospital stay.
Cost-effectiveness analyses on the use of rhTSH have reported
heterogeneous results in the literature. Mernagh et al12 found that
rhTSH was cost effective (ICER, €958/QALY) in the German context,
using a Markov model and a lifetime horizon. The greatest uncertainty
in this model was the long-term development of second malignancies.
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Fig 4. Acceptability curves of recombinant human thyroid-stimulating hor-
mone (rhTSH) compared with thyroid hormone withdrawal (THW). Cost-
effectiveness acceptability curve using net–monetary benefit approach (10,000
bootstrap replicates) represents the probability (y-axis) that rhTSH is more cost
effective compared with THW at the range of willingness-to-pay thresholds
(euros per quality-adjusted life-year [QALY]) on the x-axis. By repeating this
procedure for various thresholds, a curve is generated, with a threshold on the
x-axis and probability of rhTSH to be cost effective on the y-axis. Acceptability
curves are presented here taking into account direct costs only or total (direct and
indirect) costs.
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highly cost effective, with an ICER of $1,520/QALY.13 This study,
which used a 17-week time horizon and excluded second malignan-
cies, was sensitive to the rhTSH price and to the lengths of hospital
stays and sick leaves. In the US context, the ICER of rhTSH was
$52,554/QALY over a 4-year period, and results were sensitive to
patient utility during the first weeks after the thyroidectomy, a change
in sick leave, and rhTSH cost.14 Differences in cost-effectiveness re-
sults may be explained by the clinical and economic inputs included in
these economic evaluations. First, the three previous models used
utility scores based on SF-36 data (transformed into SF-6D scores).16
In these models, the difference in utility scores between THW and
rhTSH reached 0.17 at radioiodine administration. It was lower in our
study, thus reducing the probability of rhTSH to be cost effective.
Indeed, the duration of sick leave was estimated at 11 days for THW
patients and 6.5 days (hypothesis of a 50% reduction) for rhTSH
patients in the studies by Mernagh et al.12,13 Using this hypothesis, the
incremental cost of the rhTSH strategy was low (€47 and $87 per
patient in the German and Canadian contexts, respectively). The cost
of rhTSH injections was outweighed by the reduction in sick leave and
hospital stay costs. In our study, sick leave was only shortened by 1 day,
leading to a higher incremental cost of using rhTSH (€474) and a low
probability of cost-effectiveness. Finally, differences may also be ex-
plained by the time horizon. Unlike the study by Mernagh et al,12 our
study did not consider the impact of treatment on the risk of second
malignancies because the development of second malignancies after a
single 131I administration13 remains controversial.
Our study has several strengths. First, data for the HRQoL anal-
ysis and the economic evaluation were prospectively collected along-
side a phase III randomized trial at the patient level in the 24
participating centers, and the 684 patients were representative of pa-
tients scheduled for 131I ablation in the routine clinical setting. Second,
the ESTIMABL trial provides unbiased estimates of the length of
hospital stay for ablation, the duration of sick leaves, and health state
utilities, input parameters that were associated with the greatest un-
certainties in previous modeling studies. Third, our study has the
longest longitudinal collection of HRQoL data during the initial man-
agement of patients with differentiated thyroid cancer. In previous
studies, HRQoL was measured over only 2 months after a thyroidec-
tomy. Indeed, our study was the first to prospectively assess utility
values using the EQ-5D questionnaire, as recommended by health
technology assessment agencies in the United States (Agency for
Healthcare Research and Quality)26 and Europe (National Insti-
tute for Health and Care Excellence, Haute Autorité de Santé).24,27
Fourth, the 2  2 factorial design allowed us to address whether
ablation preparation with rhTSH versus THW and the use of 1.1
GBq instead of 3.7 GBq exert an impact on HRQoL and cost-
effectiveness in one study.
Our study also has limitations. First, the EQ-5D was found to be
less sensitive in the oncology setting, especially in situations where the
degree of vitality is an important element.28 The EQ-5D tool does not
capture small changes in health that are often important in HRQoL of
patients with cancer. In the context of thyroid cancer where vitality/
fatigue is the most impacted domain by hypothyroidism, this lack of
sensitivity of the EQ-5D questionnaire may explain the small differ-
ence in QALYs between rhTSH and THW. Second, the willingness-
to-pay threshold for cost-effectiveness analyses is not well defined,
depending on societal judgment and available resources of the coun-
try. A threshold of approximately £30,000/QALY has been applied in
the United Kingdom29; it reached $50,000/QALY in the United
States30; and there is no official threshold in France.24 Here, cost-
effectiveness results were presented for a €50,000/QALY threshold, a
well-accepted threshold in France, and using acceptability curves.
Third, some data may be specific to the French context. The length of
hospital stay reflected the inpatient management for 131I administra-
tion in French centers. The French sick leave compensation system
may explain the long period of sick leave. However, because the cost
differences for the hospital stay and sick leave were small, the impact of
outpatient management or a sick leave reduction is expected to be low.
Given their unique trends in incidence and survival, costs in
patients with thyroid cancer exhibit a distinct pattern compared with
patients with other cancer types; 78% of the cost is incurred during
initial treatment and subsequent follow-up.17 With the projected in-
creased incidence and survival trends, costs will continue to escalate.
Therefore, it is essential to assess the efficiency of the initial treatment
phase. Our study showed that the main advantage of rhTSH is to avoid
the transient THW-induced decline in HRQoL. However, this QoL
benefit did not outweigh the cost of rhTSH, and the rhTSH strategy
was not cost effective for standard thresholds in the French context.
rhTSH would be cost effective if its price was lowered by 30%. Regard-
ing iodine activity, cost-effectiveness results favor using a low 131I
activity, which reduces the length of hospital stay for ablation and
overall management costs.
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Fig A1. Evolution of the utility scores during the follow-up period obtained with the EuroQol (EQ) -5D and the Short Form (SF) -36 questionnaires (transformed in
utility score using the algorithm developed by Brazier et al16) by thyroid-stimulating hormone (TSH) stimulation method. Utility scores using the SF-36 questionnaire
are lower than those based on the EQ-5D questionnaire. However, the evolution of the utility scores over the 8-month period is similar whatever the tool, as is the
difference in quality-adjusted life-years (QALYs) between thyroid hormone withdrawal (THW) and recombinant human TSH (rhTSH; estimated at 0.538 and 0.544,
respectively; difference of 0.006 QALY, using the utility scores obtained with the SF-36 questionnaire).
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Fig A2. Cost-effectiveness plane. (A) Recombinant human thyroid-stimulating hormone (rhTSH) versus thyroid hormone withdrawal (THW), with direct costs only.
With direct costs only, 95% of the 10,000 iterations were located in the northeast quadrant (rhTSH results in gains in quality-adjusted life-years [QALYs] at additional
costs compared with THW), whereas 5% of the iterations were located in the northwest quadrant (less effective and less expensive). (B) rhTSH versus THW, with total
costs (direct and indirect). (C) Iodine-131 (131I) 1.1 GBq versus 3.7 GBq, with direct costs only. When only direct costs were considered, 81.1% of the iterations were
located in the southwest quadrant (loss in QALY and decrease in cost), and 18.9% of the iterations were located in the southeast quadrant (gain in QALY and decrease
in cost). (D) 131I 1.1 GBq versus 3.7 GBq, with total costs (direct and indirect). Results are presented in a radar screen format, where the x-axis shows the difference
in QALYs and the y-axis shows the difference in costs between two strategies (either the two stimulation methods or the two radioiodine activities), where dots
represent the 10,000 replications.
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Fig A4. Probability that recombinant human thyroid-stimulating hormone would be cost effective compared with thyroid hormone withdrawal if its price was reduced
by 10% and 30% (total costs). QALY, quality-adjusted life-year.
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